In conclusion, our study showed that ADAMTS13 level before rt-PA thrombolysis was decreased in AIS patients with 90-days mRS >2, but was not an independent predictor for clinical outcomes. The gene discussed is ADAMTS13; the disease is androgen insensitivity syndrome.